Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc

Bullboard Posts

Comment by logical1234on Jan 15, 2006 7:50pm

202 Views

Post# 10178489

RE: It's gonna be a bad year - not so

Thromboclear's schedule target was always 2006. The partner had some work to do as far as setting up manufacturing (difficult for this drug), and getting FDA approval. So the fact that it is not yet in the market is not unexpected. Also, the partner insisted that everything be kept in secrecy for competitive business reasons. Hence the lack of regular updates. So there is nothing sinister about ThromboClear up to now.

Bullboard Posts

Gold Flora's Gramlin holds court in California cannabis market